Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Grit AndersenGursharan SinghSundara Moorthi Nainar MurugesanRajesh GogineniNirant SharmaJayanti PandaAshwani MarwahSubramanian LoganathanSandeep N AthalyePublished in: Diabetes, obesity & metabolism (2023)
PK and PD equivalence was shown between Biocon's Insulin-N and Humulin-N in healthy subjects, and both treatments were well tolerated and considered safe.